FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 2054	19
-----------------------	----

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
hours per response:	0.5					

			or Section 30(ff) of the investment Company Act of 1940					
Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
<u>Durgam Sur</u>	esh K.		There contains therepres, the [1101]		Director	10% Owner		
				_ X	Officer (give title	Other (specify		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)	below)		
C/O INTRA-CELLULAR THERAPIES, INC.			01/08/2021	Chief Medical Officer				
430 EAST 29T	H STREET							
			4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group Filir	ng (Check Applicable		
(Street)				Line)				
NEW YORK	NY	10016		X	Form filed by One Re	porting Person		
—————			_		Form filed by More that Person	an One Reporting		
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11150.4)
Common Stock	01/08/2021		M		13,092	A	(1)	21,851	D	
Common Stock	01/11/2021		S ⁽²⁾		4,267	D	\$32.13(3)	17,584	D	
Common Stock	01/11/2021		S ⁽²⁾		100	D	\$31.6	17,484	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and 7. Title and Amount 1. Title of 3. Transaction 3A. Deemed 5. Number 8. Price of 9. Number of 10. 11. Nature Date (Month/Day/Year) Derivative Conversion Execution Date, Expiration Date (Month/Day/Year) of Securities derivative Ownership Derivative Derivative or Exercise Price of Derivative Security Underlying Derivative Security (Instr. 3 and 4) Security (Instr. 3) if any (Month/Day/Year) Code (Instr. Security (Instr. 5) Securities Form: **Beneficial** Direct (D) or Indirect (I) (Instr. 4) 8) Securities Beneficially Ownership Acquired (A) or Disposed Owned Following Reported Transaction(s) (Instr. 4) of (D) (Instr 3, 4 and 5) Amount or Number Expiration Date Date Code v (A) (D) Exercisable Title Shares Restricted (4) (5) (5) 01/08/2021 13,092 13,092 \$0.00 13,093 D Stock Units M Stock

Explanation of Responses:

- 1. Restricted stock units convert into common stock on a one-for-one basis.
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2020. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.77 to \$32.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above
- 4. Each restricted stock unit represents a contingent right to receive one share of common stock.
- 5. On January 8, 2019, the reporting person was granted 39,277 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

/s/ Lawrence J. Hineline, 01/12/2021 Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.